Tracking and reducing long-term side effects of therapy through prevention and intervention.
Investigators
Tyler Ketterl, MD, MS
Assistant Professor
Bio: Tyler G. Ketterl, MD, MS is an attending physician at Seattle Children’s Hospital and Assistant Professor at the University of Washington School of Medicine. Dr. Ketterl is the Medical Director of the Adolescent and Young Adult Oncology Program. Dr. Ketterl holds triple board certifications in Internal Medicine, Pediatrics and Pediatric Hematology/Oncology. He completed his Internal Medicine and Pediatrics Residency at the University of Minnesota, Pediatric Hematology/Oncology fellowship at the University of Washington, and his Masters in Science in Epidemiology with a focus on clinical research methods at the University of Washington. In July of 2018, Dr. Ketterl joined the faculty at Seattle Children’s Hospital and the University of Washington. Dr. Ketterl’s work currently focuses on the long-term impact of cancer therapy on adolescent and young adult survivors of cancer. Of particular interest to Dr. Ketterl is developing interventions that could prevent early morbidity and mortality from type 2 diabetes and cardiovascular disease in adolescent and young adult survivors of cancer. Dr. Ketterl also has interest and expertise in germ cell tumors and fertility preservation methods.
Research interests: Long-term impact of cancer therapy on adolescent and young adult survivors of cancer, metabolic syndrome, sarcopenic obesity, exercise interventions for cancer survivors, risk-behavior screening in AYA cancer patients
Kasey Leger, MD, MSc
Associate Professor
Bio: My research focus on cardiotoxicity centers largely on early biomarkers of anthracycline-induced cardiac injury and cardiomyopathy risk prediction. Additionally, I am committed to optimizing strategies of cardioprotection, primary and ultimately secondary wherein validated risk prediction models are critical. I lead the Children’s Oncology Group (COG) Myeloid Cardiotoxicity Working Group and am the cardiac chair of the ongoing COG Phase III randomized trial for patients with de novo AML comparing standard therapy to CPX-351 (AAML1831). This large, multi-institutional trial will assess strategies to mitigate cardiotoxicity and leverage a large, high-risk cohort to capture detailed cardiac phenotyping by echocardiographic measures of cardiac function and mechanics and circulating biomarkers of cardiac injury and stress. Additionally, I am the principal investigator of a cardiotoxicity biomarker cohort study at Seattle Children’s in which we are studying circulating microRNAs, high sensitivity troponin, myocardial deformation imaging (strain), and other novel blood and imaging based markers of cardiotoxicity.
Research interest: Early identification and prevention of cancer therapy-induced cardiovascular disease
Rebecca Ronsley, MD, FRCPC
Assistant Professor of Pediatrics
Bio: Dr. Ronsley completed her Bachelor of Science in Anatomy and Cell Biology at McGill University and her Medical Degree at the University of Toronto. Subsequently, she completed Pediatrics Residency, Pediatric Endocrinology training and Pediatric Hematology, Oncology & Bone Marrow Transplant Fellowship at the University of British Columbia, followed by a Fellowship in Pediatric Neuro-Oncology at Nationwide Children’s Hospital in Columbus, Ohio. She is an Attending Physician and Pediatric Oncologist in the Brain Tumor Program at Seattle Children’s Hospital. She is the Program Director for the Pediatric Neuro-Oncology Fellowship and Education Lead for the Brain Tumor Program at Seattle Children’s Hospital. She is a Clinician Scholar and is involved with local (including our BrainChild/CAR-T trials) and national trials to develop novel therapies for difficult-to-treat pediatric brain tumors. Dr. Ronsley is also passionate about morbidity reduction for survivors of pediatric CNS tumors and collaborates locally and nationally within the Childhood Cancer Survivorship Study and the International CNS Germ Cell Tumor Consortium.
Research interests: Metabolic and endocrine comorbidities and infertility/gonadal failure in survivors of pediatric brain tumors
David Noyd, MD, MSCE